Drug intelligence / Profile preview

calmangafodipir + acetylcysteine

Development stage
Unknown
Lead developer
Egetis Therapeutics
Modality
Small Molecules
Administration
Intravenous
01

Overview

**calmangafodipir + acetylcysteine** is a combination therapy under investigation for treating paracetamol (acetaminophen) overdose. Calmangafodipir acts as a superoxide dismutase mimetic (SOD mimetic) designed to protect against oxidative stress and hepatotoxicity. Acetylcysteine is the established antidote for acetaminophen overdose, functioning primarily by replenishing hepatic glutathione and promoting the detoxification of reactive metabolites. Combining calmangafodipir with acetylcysteine may offer enhanced protection of liver cells, particularly in patients at higher risk for liver injury or presenting later after overdose, by mitigating oxidative damage and reducing biomarkers of hepatotoxicity[1][3][7].

Other names
calmangafodipir + NAC
02

Targets

GSH (Glutathione synthesis / redox)

Beyond the preview

Go deeper on calmangafodipir + acetylcysteine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on calmangafodipir + acetylcysteine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call